Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor lysate-pulsed autologous dendritic cell vaccine (Jonsson Comprehensive Cancer Center)
- Development stage
- Phase 2
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
This autologous dendritic cell vaccine is a cellular immunotherapy developed by the Jonsson Comprehensive Cancer Center (UCLA) for the treatment of low-grade gliomas (WHO grade II). The vaccine is produced by harvesting a patient's own dendritic cells (DCs) and loading them with antigens derived from the patient's own tumor lysate. Once re-administered intradermally, these mature DCs present tumor-specific antigens to the patient's T cells, aiming to stimulate a systemic, targeted immune response against residual or recurrent glioma cells. The therapy is currently being evaluated in Phase II clinical trials (e.g., NCT01808820) to determine its safety and efficacy in slowing tumor growth and improving survival in patients with newly diagnosed or recurrent low-grade gliomas.
- Other names
- autologous dendritic cells pulsed with tumor lysate antigenUCLA low-grade glioma DC vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on tumor lysate-pulsed autologous dendritic cell vaccine (Jonsson Comprehensive Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor lysate-pulsed autologous dendritic cell vaccine (Jonsson Comprehensive Cancer Center).